1. FDA approves Keytruda for patients with high-risk, non-muscle invasive bladder cancer
The US Food and Drug Administration (FDA) has approved Keytruda, the first anti-PD-1 monoclonal antibody (mAb) therapy, as a treatment for patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC). The therapy is intended for NMIBC patients . more details...


2. Keytruda wins FDA nod to tackle early bladder cancer with gene therapy rival closely behind
With an FDA nod Wednesday, Keytruda has become the first PD-1/L1 inhibitor approved to treat patients with superficial but high-risk non-muscle invasive bladder cancer (NMIBC) that’s unresponsive to standard Bacillus Calmette-Guerin (BCG) treatment..more details...